Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.28 Analyst target: $17.50 Upside: 433.54%
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment of antibiotic-resistant infections worldwide. The company is headquartered in Marina del Rey, California.
See the full interactive analysis & chart →Informational only — not investment advice.